RNF128 Promotes Malignant Behaviors via EGFR/MEK/ERK Pathway in Hepatocellular Carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• The ubiquitin-proteasome system is implicated in hepatocellular carcinoma (HCC) pathogenesis.
• RNF128, an E3 ubiquitin ligase, plays a role in carcinogenesis, but its specific mechanisms in HCC remain unclear.

Purpose of the Study:

• To investigate the role and oncogenic mechanisms of RNF128 in hepatocellular carcinoma (HCC).
• To evaluate RNF128 as a potential prognostic marker and therapeutic target for HCC.

Main Methods:

• Analysis of RNF128 expression in HCC tissues using tissue microarrays.
• Assessment of RNF128 expression levels via Western blot and qRT-PCR in HCC tissues and cell lines.
• In vitro and in vivo assays (knockdown/overexpression) to determine RNF128's effects on HCC cell functions and signaling pathways.

Main Results:

• RNF128 expression is significantly upregulated in HCC tissues compared to normal adjacent tissues.
• Overexpression of RNF128 enhances HCC cell proliferation, colony formation, migration, invasion, and resistance to apoptosis.
• RNF128 activates the EGFR/MEK/ERK signaling pathway; gefitinib partially reverses RNF128-induced oncogenic effects.

Conclusions:

• RNF128 promotes HCC progression through activation of the EGFR/MEK/ERK signaling pathway.
• RNF128 may serve as a novel prognostic molecular signature for HCC.
• RNF128 presents potential as a therapeutic target for HCC treatment.